May 19, 2022
RegMed Investors’ (RMi) pre-open: another session is about to be kicked down the “Street”
May 18, 2022
RegMed Investors’ (RMi) pre-open: let’s not be caught off-guard
May 17, 2022
RegMed Investors’ (RMi) pre-open: not a bouncing sector with better dribbling coming
May 16, 2022
RegMed Investors’ (RMi) pre-open: sell into strength, I do NOT trust this market
May 13, 2022
RegMed Investors’ (RMi) pre-open: I’m mostly HOLDING today, even with futures rising
May 12, 2022
RegMed Investors’ (RMi) pre-open: sector equity’ LOWS need consideration to find a sustainable footing - I can dream!
May 9, 2022
RegMed Investors’ (RMi) pre-open: sudden and extreme volatility ain’t over, time for BUYING “some” dips?
May 6, 2022
RegMed Investors’ (RMi) pre-open: a minor surge post the purge
May 5, 2022
RegMed Investors’ (RMi) pre-open: where do investors go from here?
May 4, 2022
RegMed Investors’ (RMi) pre-open: a session up for grabs
May 3, 2022
RegMed Investors’ (RMi) pre-open: what goes dramatically up, floats down
April 29, 2022
RegMed Investors’ (RMi) pre-open: What comes in a month’s end, a letdown?
April 28, 2022
RegMed Investors’ (RMi) pre-open: after being down for so long this month, it’s time for an upside/oversold bump
April 27, 2022
RegMed Investors’ (RMi) pre-open: time to BUY “some” oversold before or with an algorithmic bought rebound
April 26, 2022
RegMed Investors’ (RMi) pre-open: ride the fence
April 25, 2022
RegMed Investors’ (RMi) pre-open: a session of chance following a global sell-off
April 22, 2022
RegMed Investors’ (RMi) pre-open: a lot of some “considered” favorite cell and gene therapy companies have fallen out of favor
April 21, 2022
RegMed Investors’ (RMi) pre-open: drifting towards a set-up for the cell and gene therapy sector
April 20, 2022
RegMed Investors’ (RMi) pre-open: I am still a believer in the Icarus myth and the danger of dramatic upside flight on low volume wings
April 19, 2022
RegMed Investors’ (RMi) pre-open: after eight (8) negative closes out of twelve (12) April sessions
April 18, 2022
RegMed Investors’ (RMi) pre-open: the cell and gene therapy sector is ailing
April 14, 2022
RegMed Investors’ (RMi) pre-open: curb your enthusiasm
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2022 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.